header
January 28, 2019

In This Issue
IN THE SPOTLIGHT
MMA's Gordon Smith Named Maine's Director of Opioid Response
AMA Outlines Policy Proposals to Combat Prescription Drug Price Increases
Researchers Say Outpatient Use of Benzodiazepines Increasing
AMA Survey of States: Top Issues Facing Organized Medicine this Year
New Moves by FDA Could Increase Naloxone Access
More Information About the Origins of the Opioid Problem
Medicare-for-all plans: How Do They Compare?
PCSS Offers Free On-line 8-hour X-waiver Course for MAT
129th MAINE LEGISLATURE
MMA Legislative Call Tuesday, January 29th
Report from the State House
UPCOMING EVENTS
Upcoming Specialty Society Meetings
Webinar Presented by Baystate Financial - Sources of Retirement Income
Enrollment Underway for Maine’s Physician Executive Leadership Institute - The Advanced Course - Deadline: January 30, 2019
Identifying Substance Use Early Saves Lives! - SBIRT with Motivational Interviewing Training - 1-day Sessions Offered on Feb 2, Mar 2, Apr 6
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Psychiatric Mental Health NP - Leeds
Urgent Care Physician - South Portland, ME
PCHC in need of Pediatrician at Multiple Locations!
Outpatient Internal Medicine Physician – Bangor, Maine
Full-time Board Certified/Board Eligible MD/DO
Outpatient Family Medicine - Brunswick, Maine
Psychiatric Nurse Practitioner - Nasson Health Care
Opportunities at the VA for Volunteer Physicians
Volunteer Opportunity with Partners for World Health

 
Search Back Issues





 




Follow Us:
AMA Outlines Policy Proposals to Combat Prescription Drug Price Increases

[from the AMA Advocacy Update]

In an ongoing effort to increase drug price transparency and address the rising cost of prescription drugs, the AMA has released a two-page advocacy document "Improving Prescription Drug Price and Cost Transparency" which outlines specific policy proposals aimed at each of the key players involved in drug pricing: pharmaceutical companies, pharmacy benefit managers (PBMs) and health insurers. All these groups contribute to prescription drug cost increases that influence patient cost-sharing, prior authorization policies and patient adherence to treatment plans, which ultimately impact patient health status and outcomes.


To learn more about the AMA's grassroots campaign to expose the opaque process that pharmaceutical companies, PBMs and health insurers engage in when pricing prescription drugs, please visit TruthinRx.org.

 

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©